**Additional file 2: Table S2** Key outcomes of responders and nonresponders to insulin glargine 100 units/ml at 24 weeks by study

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Responders**  **(HbA1c <7% or ≥1% Reduction)** | **Nonresponders**  **(HbA1c ≥7% and <1% Reduction)** | ***P*value** |
| **HbA1c (mmol/mol), n; LS mean CFB (SE) at 24 weeks** | | |  |
| Buse *et al.* [20] | 677; -24 (0.55) | 193; -7 (0.77) | <0.001 |
| Jain *et al.* [21] | 184; -25 (0.55) | 33; -13 (1.42) | <0.001 |
| Rosenstock *et al.* [22] | 327; -21 (0.44) | 71; -7 (0.87) | <0.001 |
| Integrated analysis | 1188; -24 (0.44) | 297; -9 (0.66) | <0.001 |
| **HbA1c (%), n; LS mean CFB (SE) at 24 weeks** | | |  |
| Buse et al. [20] | 677; -2.16 (0.05) | 193; -0.64 (0.07) | <0.001 |
| Jain et al. [21] | 184; -2.33 (0.05) | 33; -1.15 (0.13) | <0.001 |
| Rosenstock et al. [22] | 327; -1.90 (0.04) | 71; -0.64 (0.08) | <0.001 |
| Integrated analysis | 1188; -2.16 (0.04) | 297; -0.78 (0.06) | <0.001 |
| **Dose (units/kg/day), n; LS mean (SE) at 24 weeks** | | |  |
| Buse *et al.* [20] | 676; 0.43 (0.01) | 193; 0.46 (0.02) | 0.100 |
| Jain *et al.* [21] | 184; 0.45 (0.02) | 33; 0.37 (0.05) | 0.105 |
| Rosenstock *et al.* [22] | 327; 0.57 (0.03) | 71; 0.55 (0.05) | 0.659 |
| Integrated analysis | 1187; 0.49 (0.01) | 297; 0.47 (0.02) | 0.679 |
| **FBG (mmol/L), n; LS mean CFB (SE) at 24 weeks** | | |  |
| Buse *et al.* [20] | 190; -4.55 (0.18) | 43; -3.69 (0.31) | 0.004 |
| Jain *et al.* [21] | 182; -3.86 (0.12) | 30; -3.73 (0.29) | 0.679 |
| Rosenstock *et al.* [22] | 320; -3.72 (0.10) | 70; -2.56 (0.18) | <0.001 |
| Integrated analysis | 692; -3.97 (0.09) | 143; -3.26 (0.16) | <0.001a |
| **FBG (mg/dL), n; LS mean CFB (SE) at 24 weeks** | | |  |
| Buse *et al.* [20] | 190; -81.98 (3.24) | 43; -66.56 (5.58) | 0.004 |
| Jain *et al.* [21] | 182; -69.50 (2.12) | 30; -67.13 (5.28) | 0.679 |
| Rosenstock *et al.* [22] | 320; -67.01 (1.72) | 70; -46.16 (3.19) | <0.001 |
| Integrated analysis | 692; -71.48 (1.63) | 143; -58.77 (2.81) | <0.001a |
| Results of the integrated analysis were calculated by ANCOVA model (response = baseline of the response variable + responder + study + study-by-responder interaction + sulphonylurea use [yes/no]). *P* values presented for the integrated analysis are the difference between responders and nonresponders and are based on fixed effects meta-regression with a 2-sided α-level <0.05. Heterogeneity for the integrated analysis was assessed by study-by-responder interaction. *P* values for interaction were nonsignificant (≥0.05) for the majority of outcomes measured indicating results in these trials were relatively homogeneous. All participants had type 2 diabetes mellitus and were insulin naïve prior to study drug treatment, received insulin glargine as the only insulin therapy, and had no missing HbA1c values at 24 weeks. Abbreviations: CFB, change from baseline; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; LS, least squares; SE, standard error. aFBG *P* value for heterogeneity =0.012. | | | |